c-Abl activates RIPK3 signaling in Gaucher disease

Simple item page
dc.catalogadoryvc
dc.contributor.authorYañez Henríquez, María José
dc.contributor.authorCampos, F.
dc.contributor.authorMarín Marín, Tamara Alejandra
dc.contributor.authorKlein Posternack, Andrés David
dc.contributor.authorFuterman, A. H.
dc.contributor.authorÁlvarez, Alejandra R.
dc.contributor.authorZanlungo Matsuhiro, Silvana
dc.date.accessioned2024-06-06T19:19:44Z
dc.date.available2024-06-06T19:19:44Z
dc.date.issued2021
dc.description.abstractGaucher disease (GD) is caused by homozygous mutations in the GBA1 gene, which encodes the lysosomal β-glucosidase (GBA) enzyme. GD affects several organs and tissues, including the brain in certain variants of the disease. Heterozygous GBA1 variants are a major genetic risk factor for developing Parkinson's disease. The RIPK3 kinase is relevant in GD and its deficiency improves the neurological and visceral symptoms in a murine GD model. RIPK3 mediates necroptotic-like cell death: it is unknown whether the role of RIPK3 in GD is the direct induction of necroptosis or if it has a more indirect function by mediating necrosis-independent. Also, the mechanisms that activate RIPK3 in GD are currently unknown. In this study, we show that c-Abl tyrosine kinase participates upstream of RIPK3 in GD. We found that the active, phosphorylated form of c-Abl is increased in several GD models, including patient's fibroblasts and GBA null mice. Furthermore, its pharmacological inhibition with the FDA-approved drug Imatinib decreased RIPK3 signaling. We found that c-Abl interacts with RIPK3, that RIPK3 is phosphorylated at a tyrosine site, and that this phosphorylation is reduced when c-Abl is inhibited. Genetic ablation of c-Abl in neuronal GD and GD mice models significantly reduced RIPK3 activation and MLKL downstream signaling. These results showed that c-Abl signaling is a new upstream pathway that activates RIPK3 and that its inhibition is an attractive therapeutic approach for the treatment of GD.
dc.fechaingreso.objetodigital2024-12-12
dc.fuente.origenORCID
dc.identifier.doi10.1016/j.bbadis.2021.166089
dc.identifier.urihttps://doi.org/10.1016/j.bbadis.2021.166089
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/86568
dc.identifier.wosidWOS:000632563900014
dc.information.autorucFacultad de Ciencias Biológicas;Yañez Henríquez, María José;S/I;197587
dc.information.autorucEscuela de Medicina;Marín Marín, Tamara Alejandra;S/I;249923
dc.information.autorucFacultad de Ciencias Biológicas;Klein Posternack, Andrés David;S/I;2966
dc.information.autorucEscuela de Medicina; Zanlungo Matsuhiro, Silvana; 0000-0001-8383-9829; 72650
dc.language.isoen
dc.nota.accesoContenido parcial
dc.rightsacceso restringido
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titlec-Abl activates RIPK3 signaling in Gaucher disease
dc.typeartículo
sipa.codpersvinculados72650
sipa.trazabilidadORCID;2024-06-03
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
cAbl activates RIPK3 signaling in Gaucher disease.pdf
Size:
18.32 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas